Research - TCH - Medical Oncology - Publications
In this section:
Craft PS, Zhang Y, Brogan J, Tait N, Buckingham JM. Implementing clinical practice guidelines: a community-based audit of breast cancer treatment. Australian Capital Territory and South Eastern New South Wales Breast Cancer Treatment Group. Med J Aust. 2000 Mar 6;172(5):213-6.
Armstrong BK, Leong DC. Measuring cancer care. Aust N Z J Surg. 2000 Jan;70(1):1-2.
Cohn DA. Stuart-Harris R. Isolated central nervous system relapse of non-seminomatous germ cell tumour of the testis. A case report and review of the literature. Oncology. 61(3):184-8, 2001.
Strickland AH, Karapetis CS, Yip D, Harper PG. Adjuvant Chemotherapy for Gastro-oesophageal Cancer with Epirubicin, Cisplatin and Fluorouracil: a single centre experience (letter). Clinical Oncology 13(1) 66, 2001.
Yip D, Craft P. Colorectal carcinoma: Current Issues in Management. Current Therapeutics, 42 (7),45-50, 2001.
Yip D, Steer C, El-Nawab M, Van Der Walt, Harper P. Collecting duct carcinoma of the kidney associated with the sickle cell trait. International Journal of Clinical Practice 2001, 55;1-3.
Mann L, Baldwin D, Yip D. Alopecia: The importance of body image.Geriatric Medicine 2001, 31 (4) 19-24.
Gordard N, Yip D. The treatment of lung cancer. Geriatric Medicine 2001, 31 (7) 30-33.
Yip D, Karapetis CS, Steer C . The management of small cell lung cancer. Expert Review of Anticancer Therapy 2001 1 (2); 89-102.
Karapetis CS, Yip D, Virik K, Strickland AH, Ryder K, Cowling M, Harper PG. Epirubicin, cisplatin and prolonged or brief infusional 5-fluorouracil in the treatment of carcinoma of unknown primary site. Medical Oncology 2001, 18(1):23-32.
Karapetis CS. Strickland AH, Yip D, Van Der Walt J, Harper PG. PET and PLAP in Suspected Testicular Cancer Relapse: Beware Sarcoidosis. Annals of Oncology, 2001, 12 (10)1485-1488.
Halford S, Yip D, Karapetis CS, Steger A, Khawaja H, Harper PG. A phase II study evaluating the tolerability and efficacy of Caelyx (liposomal doxorubicin, Doxil) in the treatment of unresectable pancreatic carcinoma.Annals of Oncology 2001, 12(10), 1399-1402.
Steer C, Yip D. Symptom Palliation in advanced esophageal cancer. Current Therapeutics 2002, 43 (3); 33-35.
Steer C, Yip D. Symptom Palliation in advanced esophageal cancer. New Ethicals 2002, (4); 49-51.
Shadbolt B, Barresi J, Craft P. Self-Rated Health as a Predictor of Survival Among Patients With Advanced Cancer Journal of Clinical Oncology. 2002: 2514-2519.
Davis AJ, Tannock IF Tumor physiology and resistance to chemotherapy: repopulation and drug penetration. Cancer Treat Res. 2002;112:1-26.
Davis A.J., Chapman W., Hedley D.W., Oza A.M., Tannock I.F: Assessment of tumor cell repopulation after chemotherapy for advanced ovarian cancer. Cytometry 2003 Jan;51A(1):1-6.
Hawkins,CA, Blasioli J, McCarthy CS, Yip D, Hurwitz MD, Jain S, Cook MC. Recent onset granulomatous common variable immunodeficiency in an 88 year woman. Pathology, 2003, 35 (1) 81-82.
Yip D, Karapetis C, Strickland AH, Steer C, Holford C, Knight S, and Harper P. A dose-escalating study of oral eniluracil/5-fluorouracil plus oxaliplatin in patients with advanced gastrointestinal malignancies. Annals of Oncology 2003, 14: 864-866
Karapetis CS, Strickland AH, Yip D, Steer C, Harper PG. Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumour following chemotherapy: single-centre experience with long-term follow up. Internal Medicine Journal 2003 33: 427-435.
Burns C, Dixon T, Broom D, Smith WT, Craft PS. Family caregiver knowledge of treatment intent in a longitudinal study of patients with advanced cancer. Support Care Cancer, 2003, 11:629-637.
Barresi M, Shadbolt B, Byrne, Stuart-Harris R. The development of the Canberra symptom scorecard: a tool to monitor the physical symptoms of patients with advanced tumours. BMC Cancer 2003, 3:32.
Yip D, Allen R, Ashton C, Jain S. Radiation induced ulceration of the stomach secondary to hepatic embolization with radioactive yttrium microspheres in the treatment of metastatic colon cancer. Journal of Gastroenterology and Hepatology 2004, 19 (3): 347-349.
Gibbs P, Chao M, Jones I, Yip D. Current Evidence Supports the Use of Adjuvant Radiotherapy in Selected Patients with Rectal Cancer. Australian New Zealand Journal of Surgery 2004, 74 (3), 152-157.
Chua Y, Steer C, Yip D. Recent Advances in Small Cell Lung Cancer Cancer Treatment Reviews 2004,30(6), 521-543.
Hughes B, Yip D, Goldstein D, Waring P, Beshay V, Chong G. Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: Case report BMC Cancer 2004, 4:74.
Armstrong K, O'Connell DL, Leong D, Spigelman AD, Armstrong BK. The New South Wales colorectal cancer care survey- Part 1 surgical management.
The Cancer Council 2004.
McGrath DR, Leong DC, Armstrong BK, Spigelman AD. Continuing Medical Education. Management of colorectal cancer patients in Australia: The National Colorectal Cancer Care Survey. Australian New Zealand Journal Surgery 2004; 74:55-64.
Hughes B, Yip D, Chao M, Gibbs P, Carroll S, Goldstein D, Burmeister B, Karapetis C. Audit of post-operative chemoradiotherapy as adjuvant for resected gastroeosophageal adenocarcinoma: an Australian multicentre experience. Australian and New Zealand Journal of Surgery 2004 74 (11):951-5.
Burns CM, Dixon T, Smith WT, Craft PS. Patients with advanced cancer and family caregivers' knowledge of health and community services: a longitudinal study. Health Soc Care Community. 2004 ;12(6):488-503.
Lim L, Gibbs P, Yip D, Shapiro J, Dowling R, Smith D, Little W, Liechtenstein M. A prospective study of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable primary or secondary hepatic malignancies. Internal Medicine Journal 2005, 35(4); 222 227.
Stuart-Harris R, Odell H, Sturgiss E. Adjuvant chemotherapy for early breast cancer: Is cyclophosphamide, methotrexate and 5-fluorouracil still the standard? Asia Pacific Journal of Clinical Oncology 2005l 1(1),13-24.
Davis AJ, Craft P, Yip D. Australian Patterns of Practice Survey in the Adjuvant Systemic Treatment of Early Breast Cancer. Asia Pacific Journal of Oncology 2005 1 (1): 25-3.
Burns CM, Craft PS, Roder DM. Does emotional support influence survival? Findings from a longitudinal study of patients with advanced cancer. Support Care Cancer. 2005 May;13(5):295-302.
Yip D, Goldstein D.Adding irinotecan to first-line gemcitabine improves tumour response in advanced pancreatic cancer Abstracted from: Rocha Lima CM, Green MR, Rotche R et al, Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumour response rate J Clin Oncol 2004; 22:3776-83 (Commentary). Cancer Treatment Reviews 2005; 35 (4): 236-41.
Hughes BG, Stuart-Harris R. Docetaxel-induced myositis: report of a novel side-effect. Intern Med J. 2005 Jun;35(6):369-70.
Buchanan G, Craft PS, Yang M, Cheong A, Prescott J, Jia L, Coetzee GA, Tilley WD. PC-3 cells with enhanced androgen receptor signaling: a model for clonal selection in prostate cancer. Prostate. 2004 Sep 1;60(4):352-66.
Clarke S, Boyer M, Millward M, Underhill C, Moylan E, Yip D, White S, Childs A, Beale P, Latz J, Suri A, Iglesias J. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. Lung Cancer 2005; 49 (3): 401-12.
Grimpen F Yip D, McArthur G, Waring P, Goldstein D, Loughrey M, Beshay V, Chong G. Resistance to Imatinib Mesylate associated with low FDG-avidity on PET and acquired exon 17 mutation in Gastrointestinal Stromal Tumour (GIST). Lancet Oncology 2005; 6 (11); 851-855.
Lim L, Yip D, Shapiro JD, Dowling R, Smith D, Little A, Bailey W, Lietchenstein M ,Gibbs. A prospective study of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy BMC Cancer 2005, 5:132.
Koshy A, Buckingham JM, Zhang Y, Craft P, Dahlstrom JE, Tait N; Surgical management of invasive breast cancer: a 5-year prospective study of treatment in the Australian Capital Territory and South-Eastern New South Wales. ANZ J Surg. 2005 Sep;75(9):757-61
Craft PS, Burns CM, Smith WT, Broom DH. Knowledge of treatment intent among patients with advanced cancer: a longitudinal study. : Eur J Cancer Care (Engl). 2005;14(5):417-2
McGrath DR, Leong DC, Gibberd R, Armstrong B, Spigelman AD. Continuing Medical Education:Surgeon and hospital volume and the management of colorectal cancer patients in Australia. ANZ J Surg 2005; 75:901-10
Bromley J, Hughes BGM, Leong DCS, Buckley NA. Life-Threatening Interaction Between Complementary Medicines: Cyanide Toxicity Following Ingestion of Amygdalin and Vitamin C. Ann Pharmacotherapy 2005; 39(9):1566-9.
Armstrong K, O'Connell DL, Leong D, Yu XQ, Spigelman AD, Armstrong BK. The
New South Wales Colorectal Cancer Care Survey Part 2 - Chemotherapy Management. The Cancer Council NSW 2005.
Steer CB, Chrystal K, Cheong KA, Galani E, Marx G, Strickland AH, Yip D, Lofts F, Gallagher G, Thomas H, Harper PG. Gemcitabine and Oxaliplatin followed by Paclitaxel and Carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets: The GO-First Study. Gynaecologic Oncology 2006 103;439-445.
Tan TH, Stevenson B, Yip D. Docetaxel induced nasal septal perforation. Internal Journal of Medicine 2006 36(7):471-2.
Yip D, Karapetis C, Strickland A, Steer CB, Goldstein D. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database of Systematic Reviews 2006, Issue 3.
Burns CM, Broom DH, Smith WT, Dear K, Craft PS.Fluctuating awareness of treatment goals among patients and their caregivers: a longitudinal study of a dynamic process. Support Care Cancer, 2007, 15(2):187-96.
Tinker AV, Gebski V, Fitzharris B, Buck M, Stuart-Harris R, Beale P, Goldrick A, Rischin D. Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel--ANZGOG 02-01. Gynecol Oncol. 2007 Mar;104(3):647-53.
Young, J. Leong, D. Armstrong, K. et al, Concordance with national guidelines for colorectal cancer care in New South Wales: a population-based patterns of care study, Medical Journal of Australia, 2007;186, 292-295.
Davis AJ, Brew S, Gebski VJ, Lewis CR, Moylan E, Parnis FX, Ackland SP. Multicenter phase II study of combination chemotherapy with capecitabine and intravenous vinorelbine in patients with pretreated metastatic breast cancer Asia-Pacific Journal of Clinical Oncology 2007, 3 (1), 37-43.
Harnett P, Buck M, Beale P, Goldrick A, Allan S, Fitzharris B, de Souza P, Links M, Kalimi G, Davies T, Stuart-Harris R. Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study. Int J Gynecol Cancer. 2007 Mar-Apr;17(2):359-66.
Kanthan GL,Jayamohan J,Yip D,Conway RM. Management of metastatic carcinoma of the uveal tract: an evidence-based analysis. Clinical & Experimental Ophthalmology 2007, 35(6): 553-565.
Ruzich M, Ryan B, Owen C, Delahunty A, Stuart-Harris R. A Prospective Evaluation of Cognitive Function in Patients with Early Breast Cancer Receiving Adjuvant Chemotherapy. Asia Pac J Clin Oncol 3: 125-133, 2007
Lord SJ, Lei W, Craft P, Cawson JN, Morris I, Walleser S, Griffiths A, Parker S, Houssami N. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur J Cancer 43:1905-1917, 2007.
Burns CM, Broom D, Dear K, Smith WT, Craft PS. Fluctuating knowledge of treatment goal amongst patients and their caregivers: a longitudinal study of a dynamic process. Support Care Cancer, 15(2):187-96, 2007.
Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferative Factors in Early Breast Cancer: A Systematic Review and Meta-Analysis of 85 studies in 32,825 Patients. The Breast, 2008 Apr 30.
Pranavan G, Goldstein D,Yip D. Response of Carney's triad-related metastatic gastrointestinal stromal tumor to sunitinib. Asia Pac J Clin Oncol, 4(3),170-4, 2008.
Chua YJ, Zalcberg JR.Pancreatic cancer--is the wall crumbling?Ann Oncol.19(7):1224-30,2008.
Zalcberg JR, Desai J, Mann B, Fox S, Goldstein D, McArthur G, Clark M, Yip D. Consensus approaches to best practice management of gastrointestinal stromal tumors. Asia Pac J Clin Oncol, 4 (4), 188-198, 2008.
Chua YJ, Zalcberg JR.Progress and challenges in the adjuvant treatment of stage II and III colon cancers.Expert Rev Anticancer Ther;8(4):595-604, 2008.
Snyder RS, Boyle FM, Chan A, Craft PS, De Boer R, Mainwaring PN, McCarthy NJ, Wilcken NR. Clinical recommendations for the use of lapatinib ditosylate plus capecitabine for patients with advanced or metastatic Her2-positive breast cancer. Asia Pac J Clin Oncol, 5 (1), 4-16, 2009.
Hemmings, C, Broomfield A, Bean E, Whitehead M, Yip D. Immunohistochemical Expression of EGFR in Colorectal Carcinoma Correlates with High- But Not Low-Level Gene Amplification, as Demonstrated by CISH. Pathology 2009, 41 (4): 356-360.
Hoy, J, Neeman T,Stuart-Harris R,Davis A.Risk of venous thromboembolism in patients receiving adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide for early breast cancer. Asia-Pac J Clin Oncol 5 (2) 129-136, 2009.
Wang S, Merlin T, Kreisz F, Craft P, Hiller JE. Cost and cost-effectiveness of digital mammography compared with film-screen mammography in Australia. Aust N Z J Public Health.2009 Oct;33(5):430-6.
Thewes B, Butow P, Stuart-Harris R; Greater Southern Area Health Service Screening Collaborative Group.Does routine psychological screening of newly diagnosed rural cancer patients lead to better patient outcomes? Results of a pilot study. Aust J Rural Health. 2009 Dec;17(6):298-304.
Tan TH, Hemmings C, Stafford-Bell M, Robson S, Yip D. The successful management of two pregnancies with metastatic gastrointestinal stromal tumours. Asia Pacific Journal of Clinical Oncology 2009 5(3) 187-192.
Stuart-Harris R, Shadbolt B, Palmqvist C, Chaudri Ross HA.The prognostic significance of single hormone receptor positive metastatic breast cancer: an analysis of three randomised phase III trials of aromatase inhibitors.Breast. 2009 18(6):351-5.
Stuart-Harris R, Davis A.Optimal adjuvant endocrine therapy for early breast cancer.Womens Health (Lond Engl). 2010 6(3):383-98
Chua YJ, Michael M, Zalcberg JR, Hicks RJ, Goldstein D, Liauw W, Price T.Antitumor effect of somatostatin analogs in neuroendocrine tumors.J Clin Oncol.20;28(3), 2010.
Chua YJ, Barbachano Y, Cunningham D, Oates JR, Brown G, Wotherspoon A, Tait D, Massey A, Tebbutt NC, Chau I.Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.Lancet Oncol, 11 (3),241-8,2010.
Tan TH, Pranavan G, Haximolla HZ ,Yip D. New systemic treatment options for metastatic renal-cell carcinoma in the era of targeted therapies. Asia Pacific Journal of Clinical Oncology 2010 6(1) 5-18.
Craft PS, Buckingham JM , Dahlstrom JE, Beckmann KR, Zhang YP, Stuart-Harris R , Jacob G, Roder D, Tait N. Variation in the management of early breast cancer in rural and metropolitan centres: Implications for the organisation of rural cancer services. Breast, 2010 19(5)396-401.
Karapetis CS, Cheong KA, Yip D, Strickland AH, Steer C, Marx G, Yip S, Chrystal L, Harper PG. A phase I/II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil (5FU) and sodium folinate (ECSF) in patients with advanced oesophago-gastric carcinoma. Asia Pacific Journal of Clinical Oncology 2010, 6(1);298-305.
Chua YJ.Pathological complete response: still a relevant endpoint in rectal cancer? Lancet Oncol. 2010 Sep;11(9):807-8.
Grimison PS, Stockler MR, Thomson DB, Olver IN, Harvey VJ, Gebski VJ, Lewis CR, Levi JA, Boyer MJ, Gurney H, Craft P, Boland AL, Simes RJ, Toner GC.Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial.J Natl Cancer Inst. 2010 Aug 18;102(16):1253-62.
Okines AF, Ashley SE, Cunningham D, Oates J, Turner A, Webb J, Saffery C, Chua YJ, Chau I. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial.J Clin Oncol. 2010 Sep 1;28(25):3945-50.
Talaulikar D, Tridgell D, Leong D, Dahlstrom JE,Cherian M, Prosser I, Sunderland K. Novel therapeutic option for orbital atypical lymphoid hyperplasia. 2010, 38(9),892-894.
Kosmider S, Tan TH, Yip D, Dowling R, Lichtenstein M, Gibbs P, Radioembolization in Combination with Systemic Chemotherapy as First-line Therapy for Liver Metastases from Colorectal Cancer, Journal of Vascular and Interventional Radiology, 2011 22 (6); 780-786.
Goel S, Chirgwin J, Francis P, Stuart-Harris R, Dewar J, Mileshkin L, Snyder R, Michael M, Koczwara B.Rational use of trastuzumab in metastatic and locally advanced breast cancer: implications of recent research.Breast. 2011 Apr;20(2):101-10.
Webber K, Cooper A, Kleiven H, Yip D, Goldstein D. Management of metastatic renal cell carcinoma in the era of targeted therapies. Internal Medicine Journal 2011 41 (8); 594-605.
Rezo A, Dahlstrom J, Shadbolt B, Rodins K, Zhang Y, Davis A. Tumor Size and Survival in Multicentric and Multifocal Breast Cancer. The Breast 2011; 20:259-263
Wong R, Cunningham D, Barbachano Y, Saffery C, Valle J, Hickish T, Mudan S, Brown G, Khan A, Wotherspoon A, Strimpakos AS, Thomas J, Compton S, Chua YJ, Chau I.A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.Annals of Oncology. 2011 Sep;22(9):2042-8.
Beckmann KR, Buckingham J, Craft P, Dahlstrom JE, Zhang Y, Roder D, Stuart-Harris R. Clinical characteristics and outcomes of bilateral breast cancer in an Australian cohort.Breast. 2011 Apr;20(2):158-64.
Subramaniam K, Tucker K, Craft P, Pavli P. Should patients be screened for hereditary cancer syndromes before starting anti-TNF-á therapy? Inflamm Bowel Dis. 2011 Nov;17(11):E151-2.
Grimison P, Phillips F, Butow P, White K, Yip D, Sardelic F, Underhill C, Tse R, Simes R, Turley K, Goldstein D. Are Visiting Oncologists Enough? A Qualitative Study of the Needs of Australian Rural and Regional Cancer Patients and Health Professionals. Asia Pacific Journal of Clinical Oncology 2012 (Accepted for publication) doi: 10.1111/ajco.12014.
Chua Y, Steer C, Yip D. Recent Advances in Small Cell Lung Cancer. In Carafaro RL (ed). Focus on Lung Cancer Research. Nova Science Publishers, NY 2004
Yip D, Gorddard N. Oncological Emergencies:Diagnosis and Management. In: Robotin M, Olver I, Girgis, A (Eds)When Cancer Crosses Disciplines: A Physician's Handbook. Imperial College Press, London, 2010.
Zalcberg J, Yip D, Hemmings C, Mann B, Blanke C. Gastrointestinal Stromal Tumors. In: Blanke C, Rodel C, Talamonti MS (Eds) Gastrointestinal Oncology: A Practical Guide. Springer-Verlag: Berlin Heidelberg 2011.
Tan TH, Lees J, Pranavan G, Yip D. New Systemic Approaches in the Treatment of Metastatic Renal Cell Carcinoma. In: Amato R (Ed) Emerging Research and Treatments in Renal Cell Carcinoma. p.369-406, InTech: Rijeka, 2012.